Trade Report: The Entellus Medical Inc. (ENTL) VP Sold $222,171.03 in Stock

The Entellus Medical Inc. (ENTL) VP Sold $222,171.03 in Stock

Entellus Medical Inc. (NASDAQ:ENTL) VP Margaret A. Boiano sold 11,103 shares of the business’s stock in a transaction dated Thursday, October 13th. The shares were sold at an average price of $20.01, for a total transaction of $222,171.03. The sale was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Entellus Medical Inc. (NASDAQ:ENTL) traded up 3.98% during midday trading on Friday, reaching $20.40. 50,135 shares of the company’s stock were exchanged. The company’s market cap is $384.52 million. Entellus Medical Inc. has a 12-month low of $13.72 and a 12-month high of $22.63. The stock’s 50 day moving average price is $20.09 and its 200 day moving average price is $18.19.

Entellus Medical (NASDAQ:ENTL) last posted its earnings results on Wednesday, August 3rd. The medical technology company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.08. The business had revenue of $18.73 million for the quarter, compared to the consensus estimate of $18.48 million. Entellus Medical had a negative net margin of 33.54% and a negative return on equity of 41.83%. The company’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter last year, the firm posted ($0.15) EPS. Equities analysts anticipate that Entellus Medical Inc. will post ($1.23) earnings per share for the current fiscal year.

Several equities analysts recently issued reports on the stock. BTIG Research reiterated a “buy” rating on shares of Entellus Medical in a research report on Wednesday, June 29th. Canaccord Genuity reiterated a “buy” rating and set a $23.00 price target on shares of Entellus Medical in a research report on Wednesday, June 29th. Zacks Investment Research upgraded shares of Entellus Medical from a “hold” rating to a “buy” rating and set a $20.00 price objective on the stock in a report on Monday, August 8th. Deutsche Bank AG assumed coverage on shares of Entellus Medical in a report on Thursday, October 6th. They issued a “buy” rating and a $26.00 price objective on the stock. Finally, Bank of America Corp. restated a “buy” rating on shares of Entellus Medical in a report on Monday, July 18th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $22.75.

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Schwab Charles Investment Management Inc. increased its position in Entellus Medical by 1.2% in the second quarter. Schwab Charles Investment Management Inc. now owns 17,025 shares of the medical technology company’s stock worth $312,000 after buying an additional 210 shares during the period. Grandeur Peak Global Advisors LLC increased its position in Entellus Medical by 218.1% in the second quarter. Grandeur Peak Global Advisors LLC now owns 21,950 shares of the medical technology company’s stock worth $401,000 after buying an additional 15,050 shares during the period. Murphy Michael R increased its position in Entellus Medical by 30.1% in the second quarter. Murphy Michael R now owns 627,441 shares of the medical technology company’s stock worth $11,463,000 after buying an additional 145,304 shares during the period. Ghost Tree Capital LLC increased its position in Entellus Medical by 9.1% in the second quarter. Ghost Tree Capital LLC now owns 120,000 shares of the medical technology company’s stock worth $2,192,000 after buying an additional 10,000 shares during the period. Finally, State Street Corp increased its position in Entellus Medical by 89.2% in the second quarter. State Street Corp now owns 96,040 shares of the medical technology company’s stock worth $1,753,000 after buying an additional 45,267 shares during the period. 66.22% of the stock is currently owned by institutional investors and hedge funds.

Entellus Medical Company Profile

Related posts

Leave a Comment